Transthyretin (TTR) Amyloidosis Market Overview
The Transthyretin (TTR) amyloidosis market is likely to register a robust growth over the forecast period. Transthyretin (TTR) amyloidosis is a health condition characterized by anomalous deposits of a protein named amyloid (amyloidosis) in a person’s tissues and organs. It usually affects autonomic neuropathy or peripheral neuropathic system and cardiac system. Amyloidosis symptoms are often ambiguous having similarity to symptoms caused by other conditions. The symptoms vary based on the location and type of the amyloid deposits. Primarily, three major types of transthyretin amyloidosis have been identified. The neuropathic type of transthyretin amyloidosis affects the autonomic and peripheral nervous systems, resulting in trouble controlling bodily functions and peripheral neuropathy. The leptomeningeal type of transthyretin amyloidosis mostly affects the central nervous system. The cardiac type of Transthyretin (TTR) amyloidosis puts patients at the risk of orthostatic hypertension, cardiomegaly, and arrhythmia.
The surging African American population, increasing number of ATTR therapeutic drug launches, increasing average income of individuals, and growing healthcare awareness among people serves as key factors for driving the Transthyretin (TTR) amyloidosis market growth.
However, progress of the market can be restricted by strict governing policies, incorrect diagnosis of TTR ailments, restraints on clinical trials, and high cost of TTR drugs. Unavailability of advanced diagnostic methods in the middle-income nations and lack of knowledge about Transthyretin amyloidosis acts as major challenges to the market.
Transthyretin (TTR) Amyloidosis Market Segmentation
The worldwide Transthyretin (TTR) amyloidosis market has been segmented based on treatment, gender, end-user, and disease type. Based on treatment, the market has been segmented into organ transplantation, RNAi therapy, small molecules treatment, and others. Small molecules treatment has been sub-segmented as diflunisal and tafamidis. Based on gender, the market has been segmented into male and female. Based on end-user, the market has been segmented into ambulatory surgical centers, hospitals and clinics, and others. Based on disease type, the market has been segmented into Transthyretin (TTR) familial amyloid polyneuropathy, Transthyretin (TTR) familial amyloid cardiomyopathy, and others.
ALSO READ :https://teletype.in/@sapanas/49kOCbRVn
Transthyretin (TTR) Amyloidosis Market Regional Analysis
The Americas hold the largest market share for Transthyretin (TTR) amyloidosis. The growth is owing to the rising occurrence of amyloidosis among adults and older population and increasing elderly population. For instance, a report published by ASCO Journal in 2016 stated that almost 4,000 people suffered from amyloidosis each year in the United States. Additionally, increasing government funding, technologically advanced diagnostic equipment, and surging research initiatives in advanced medical treatment options are likely to drive the market. The existence of leading pharmaceutical brands such as Merck and Pfizer also boost the market in this region.
ALSO READ :http://www.marketwatch.com/press-release/middle-east-and-africa-smokeless-tobacco-market-analysis-competitive-analysis-industry-segments-development-opportunities-and-forecast-to-2023-2021-01-06
Europe represents the second largest share in the global Transthyretin (TTR) amyloidosis market. The Europe market has been anticipated to grow remarkably over the forecast period. The growth is owing to soaring healthcare expenditure, availability of progressive treatment facilities, amplifying demand for improved healthcare infrastructure collectively with government initiatives for healthcare reform. In the U.K., almost 60 new cases of Transthyretin (TTR) amyloidosis are reported every year. Furthermore, increased affordability coupled with well-established medical device manufacturers accelerate the market to a great extent. However, increasing incidences of wrong diagnosis and the inefficiency of treatment procedures are likely to restrict the growth in the Europe market.
Asia Pacific market has been fast expanding owing to rising aged population. Moreover, increasing patient pool, government initiatives to enhance the healthcare facility, availability of favorable insurance reimbursement policies, and a rapid adoption of advanced technology are likely to stimulate the Transthyretin (TTR) amyloidosis market.
ALSO READ :http://www.marketwatch.com/press-release/anti-corrosion-coating-market-business-opportunities-leading-players-covid-19-overview-industry-statistics-revenue-and-future-investments-2023-2021-01-05
The Middle East and Africa market has been anticipated to register least growth owing to limited access to treatment facilities and lack of health awareness. In the Middle East, Saudi Arabia and the United Arab Emirates are the largest markets. The market growth has been attributed to the easy accessibility of specialty care centers and growth of healthcare industry. However, the market is expected to witness steady development due to the genetical predisposition of Africans for transthyretin amyloidosis and administrative initiatives to excel the quality of healthcare in the region.
Transthyretin (TTR) Amyloidosis Market Key Players
The global Transthyretin (TTR) amyloidosis market has been dominated by key players such as Pfizer, Alnylam Pharmaceuticals, Ionis Pharmaceuticals Inc., Arcturus Therapeutics, Corino Therapeutics Inc, and Proclara Bioscience.